PBC Today
Potential risk factors
Factors like race, age, disease severity, and presence of symptoms can increase risk of disease progression5–12
Non-response of treatment
ALP is not adequately controlled in up to 40% of patients treated with UDCA*2–4
Second-line treatments are needed to manage PBC progression and lessen symptom impact13
To date, second-line treatments:
May have incomplete effects, with limitations in managing the underlying cholestasis and inflammation of PBC12,14,15
May worsen PBC symptoms, such as pruritus, to the point of causing treatment discontinuation12,14
Footnotes
*Exact values depend on the response criteria used, and include the Barcelona, Paris I, Paris II, Mayo, Toronto, GLOBE, PBC-UK, and Rotterdam criteria2-4
Abbreviations
ALP, alkaline phosphatase; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.
References
- IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024.
- Trivedi HD et al. Frontline Gastroenterol. 2017;8(1):29–36.
- Invernizzi P et al. Dig Liver Dis. 2017;49(8):841–846.
- Hirschfield GM et al. Expert Rev Gastroenterol Hepatol. 2021;15(8):929–939.
- Corpechot C et al. Clin Res Hepatol Gastroenterol. 2022;46(1):101770.
- Carbone M et al. Gastroenterology. 2013;144(3):560–569. e7.
- Peters MG et al. Hepatology. 2007;46(3):769–775.
- Cholankeril G et al. Clin Gastroenterol Hepatol. 2018;16(6):965–973. e2.
- Galoosian A et al. Dig Dis Sci. 2020;65(2):406–415./li>
- Sayiner M et al. Hepatology. 2019;69(1):237–244.
- European Association for the Study of the Liver. J Hepatol. 2017;67(1):145–172.
- Lindor KD et al. Hepatology. 2019;69(1):394–419.
- Barba Bernal R et al. Turk J Gastroenterol. 2023;34(2):89–100.
- Levy C. Clin Gastroenterol Hepatol. 2023;21(8):2076–2087.
- Montano-Loza AJ & Corpechot C. Clin Gastroenterol Hepatol. 2021;19(11):2241–2251.
Resources
- PBC
- IQIRVO MoA
- The ELATIVE trial: Study design & baseline characteristics
- The ELATIVE trial: Efficacy
- The ELATIVE trial: Safety data
- IQIRVO Safety Data
- Dosing
- Resources